Beaton Management Co. Inc. lessened its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 22,160 shares of the company’s stock after selling 90 shares during the period. Johnson & Johnson makes up about 2.4% of Beaton Management Co. Inc.’s holdings, making the stock its 8th largest position. Beaton Management Co. Inc.’s holdings in Johnson & Johnson were worth $3,927,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Family CFO Inc purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $26,000. RE Dickinson Investment Advisors LLC boosted its position in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC boosted its position in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the last quarter. Professional Financial Advisors LLC boosted its position in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at $38,000. Institutional investors and hedge funds own 68.59% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on JNJ. SVB Leerink lowered their target price on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Morgan Stanley boosted their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Finally, Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $189.89.
Johnson & Johnson Trading Up 0.8 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. Johnson & Johnson’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.48 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.